Prognostic Value of p53 and bcl-2 Expression in Patients Treated with Breast Conservative Therapy.
10.3346/jkms.2010.25.2.235
- Author:
Kyubo KIM
1
;
Eui Kyu CHIE
;
Wonshik HAN
;
Dong Young NOH
;
In Ae PARK
;
Do Youn OH
;
Seock Ah IM
;
Tae You KIM
;
Yung Jue BANG
;
Sung W HA
Author Information
1. Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea. swha@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Breast Neoplasms;
bcl-2;
p53
- MeSH:
Adult;
Aged;
Breast Neoplasms/metabolism/radiotherapy/*surgery;
Combined Modality Therapy;
Disease-Free Survival;
Female;
Humans;
*Mastectomy, Segmental;
Middle Aged;
Multivariate Analysis;
Phenotype;
Prognosis;
Proto-Oncogene Proteins c-bcl-2/genetics/*metabolism;
Receptors, Estrogen/metabolism;
Tumor Suppressor Protein p53/genetics/*metabolism
- From:Journal of Korean Medical Science
2010;25(2):235-239
- CountryRepublic of Korea
- Language:English
-
Abstract:
Prognostic value of p53 and bcl-2 expression on treatment outcome in breast cancer patients has been extensively evaluated, but the results were inconclusive. We evaluated the prognostic significance of these molecular markers in patients treated with breast conserving surgery and radiotherapy. One hundred patients whose immunostaining of p53 and bcl-2 expression was available among 125 patients who underwent radiotherapy after breast conserving surgery and axillary lymph node dissection were enrolled into this study. Eighty-seven patients also received adjuvant chemotherapy and/or hormonal therapy. Conventional clinicopathologic variables and treatment-related factors were also considered. The 5-yr loco-regional relapse-free and distant metastasis-free survival rates were 91.7% and 90.9%, respectively. On univariate analysis, age, T stage and the absence of bcl-2 & estrogen receptor (ER) expression were associated with loco-regional relapse-free survival. When incorporating these variables into Cox proportional hazard model, only bcl-2(-)/ER(-) phenotype was an adverse prognostic factor (P=0.018). As for the distant metastasis-free survival, age, T stage, and p53 expression were significant on univariate analysis. However, p53 expression was the only prognosticator on multivariate analysis (P=0.009). A bcl-2(-)/ER(-) phenotype and p53 expression are useful molecular markers predicting loco-regional relapse-free and distant metastasis-free survival, respectively, in patients treated with breast conserving surgery and radiotherapy.
